Piper Sandler Cuts CVS Health (NYSE:CVS) Price Target to $99.00

CVS Health (NYSE:CVS) had its price objective cut by Piper Sandler from $101.00 to $99.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have an overweight rating on the pharmacy operator’s stock.

Several other analysts also recently commented on the stock. Morgan Stanley upped their price target on shares of CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Barclays raised their price objective on CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of CVS Health in a research note on Wednesday, December 10th. Argus cut their target price on shares of CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, January 28th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of CVS Health in a research note on Monday, December 29th. Twenty investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.95.

CVS Health Stock Up 1.5%

Shares of NYSE:CVS opened at $73.57 on Tuesday. The business has a fifty day moving average of $75.93 and a two-hundred day moving average of $77.68. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80. The stock has a market cap of $93.59 billion, a P/E ratio of 53.31, a PEG ratio of 0.76 and a beta of 0.51. CVS Health has a 52-week low of $58.35 and a 52-week high of $85.15.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The firm had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. During the same quarter in the prior year, the firm posted $1.19 earnings per share. CVS Health’s quarterly revenue was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, research analysts expect that CVS Health will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, May 4th. Investors of record on Thursday, April 23rd will be issued a $0.665 dividend. The ex-dividend date of this dividend is Thursday, April 23rd. This represents a $2.66 annualized dividend and a dividend yield of 3.6%. CVS Health’s dividend payout ratio (DPR) is 192.75%.

Institutional Trading of CVS Health

Hedge funds have recently added to or reduced their stakes in the business. SOA Wealth Advisors LLC. boosted its holdings in CVS Health by 36.9% during the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after buying an additional 131 shares in the last quarter. Alteri Wealth LLC increased its holdings in CVS Health by 3.2% in the third quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator’s stock worth $316,000 after buying an additional 131 shares during the last quarter. TOWER TRUST & INVESTMENT Co lifted its position in shares of CVS Health by 0.8% in the fourth quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock worth $1,247,000 after buying an additional 132 shares during the last quarter. Holistic Financial Partners boosted its position in CVS Health by 4.1% during the third quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator’s stock worth $256,000 after purchasing an additional 133 shares during the period. Finally, CYBER HORNET ETFs LLC lifted its position in CVS Health by 4.1% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after acquiring an additional 134 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Company rolling out new store formats and refocusing on health care — CVS is testing a “radical” new store concept and accelerating a rollout of smaller, pharmacy‑only locations (about 20 this year) as it repositions toward health services and away from a pure convenience/retail model. Investors view this as a growth and margin improvement initiative. CVS adds a radical new store concept CVS Accelerates Rollout of New Pharmacy-Only Store Format
• Positive Sentiment: Plan to expand brick‑and‑mortar footprint after years of closures — CVS plans to open dozens of new stores (reports cite up to ~60 in 2026), a sign management sees attractive returns on selected new locations. This supports revenue growth expectations. CVS plans to open 60 new stores in 2026 after years of closures
• Positive Sentiment: Analyst and retail investor attention is increasing — Zacks and other outlets note heavy investor interest and bullish analyst coverage (consensus analysts still show meaningful upside for the stock), which can attract buying momentum. CVS Health Corporation (CVS) is Attracting Investor Attention
• Neutral Sentiment: Omnicare sale process advancing under court supervision — CVS subsidiary Omnicare entered an asset purchase agreement with GenieRx as a stalking‑horse bidder; outcome could free up value or create one‑time charges depending on final terms. Impact is uncertain until the process concludes. Omnicare Advances Court-Supervised Process
• Negative Sentiment: Piper Sandler trimmed expectations — at least one firm has lowered its outlook/price target, which could weigh on sentiment if other boutiques follow. Piper Sandler Has Lowered Expectations for CVS Health Stock Price
• Negative Sentiment: Regulatory/legal risk around insulin pricing — reports note CVS is under analyst scrutiny following a proposed FTC settlement related to insulin pricing; this creates potential liability and near‑term uncertainty. CVS Health (CVS) Under Analyst Spotlight Following Proposed FTC Settlement

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.